Cue Biopharma, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
5.23M
on 2026-06-30, from 1.62M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-30 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
$300.0M
S-3 of 2026-03-16. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$12.7M
Jefferies, agreement of 2021-10-01. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
357K
Warrants of every class as tagged in the XBRL facts on 2023-09-30. Adjusted for the 1-for-30 reverse split. 10-Q ↗
Cash
1.4 quarters
$17.4M on 2026-06-30 ÷ $12.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-07-09 | Private placement incl. 0.09M pre-funded | 1,505,571 | $33.21 | $50.0M | 8-K ↗ |
| 2026-04-30 | Private placement incl. 2.73M pre-funded | 5,454,544 | not read | $30.0M | 8-K ↗ |
| 2025-12-19 | Public offering incl. 23.21M pre-funded | 35,714,286 | $0.28 | $10.0M | 424B5 ↗ |
| 2025-04-14 | Public offering incl. 11.47M pre-funded | 24,999,996 | $0.79 | $19.7M | 424B5 ↗ |
Also on file: a 1-for-30 reverse split, 2026-04-22 8-K ↗